Comparative Pharmacology
Head-to-head clinical analysis: AUGMENTIN 250 versus CLOXAPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUGMENTIN 250 versus CLOXAPEN.
AUGMENTIN '250' vs CLOXAPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking. Clavulanate is a beta-lactamase inhibitor that irreversibly binds to beta-lactamases, preventing hydrolysis of amoxicillin.
Cloxapen inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBPs involved in the transpeptidation step of peptidoglycan cross-linking. It is resistant to staphylococcal beta-lactamases.
One 250 mg amoxicillin/125 mg clavulanate tablet orally every 8 hours for 7-10 days.
Oral: 250-500 mg every 6 hours. IV: 1-2 g every 4-6 hours.
None Documented
None Documented
Amoxicillin: 1.0-1.3 hours; clavulanate: 1.0-1.5 hours; prolonged in renal impairment (up to 7 hours for amoxicillin in anuria).
Terminal elimination half-life 1.5-2 hours; prolonged to 2.5-4 hours in severe renal impairment; clinical context: requires frequent dosing in normal renal function
Renal: ~50-70% as amoxicillin, ~25-40% as clavulanate unchanged; biliary/fecal: minor (10-15% combined).
Renal 70-80% as unchanged drug and active metabolite; biliary 5-10%; fecal <5%
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic